Silence Therapeutics (SLN) Non-Current Receivables (2019 - 2020)
Silence Therapeutics recorded quarterly Non-Current Receivables of $40.9 million in Q2 2020, up 794885.59% quarter-over-quarter from $5142.9 in Q4 2019.
Silence Therapeutics' Non-Current Receivables history runs 2 years deep, the most recent figure standing at $40.9 million for Q2 2020.
- In Q2 2020, Non-Current Receivables changed N/A year-over-year to $40.9 million; the TTM figure through Jun 2020 stood at $40.9 million (changed N/A YoY), while the FY2019 annual figure was $5107.4, changed N/A from the prior year.
- Non-Current Receivables came in at $40.9 million for Q2 2020 at Silence Therapeutics, up from $5142.9 in the prior quarter.
- In the past five years, Non-Current Receivables ranged from a high of $40.9 million in Q2 2020 to a low of $5142.9 in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 40.89 Mn |
| Dec 31, 2019 | 5,142.90 |